Peak Asset Management LLC Increases Position in Merck & Co., Inc. (NYSE:MRK)

Peak Asset Management LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 0.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,296 shares of the company’s stock after buying an additional 128 shares during the quarter. Peak Asset Management LLC’s holdings in Merck & Co., Inc. were worth $2,213,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of MRK. WealthPlan Investment Management LLC boosted its position in Merck & Co., Inc. by 3,477.6% in the 3rd quarter. WealthPlan Investment Management LLC now owns 10,232 shares of the company’s stock valued at $1,053,000 after buying an additional 9,946 shares during the period. Wealthspire Advisors LLC raised its stake in shares of Merck & Co., Inc. by 37.0% during the third quarter. Wealthspire Advisors LLC now owns 57,526 shares of the company’s stock valued at $5,922,000 after acquiring an additional 15,529 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Merck & Co., Inc. by 8.0% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,473,631 shares of the company’s stock valued at $254,660,000 after purchasing an additional 183,345 shares during the period. Cornerstone Wealth Management LLC grew its stake in Merck & Co., Inc. by 7.0% in the third quarter. Cornerstone Wealth Management LLC now owns 20,992 shares of the company’s stock worth $2,161,000 after purchasing an additional 1,377 shares in the last quarter. Finally, Great Valley Advisor Group Inc. increased its holdings in Merck & Co., Inc. by 10.8% during the 3rd quarter. Great Valley Advisor Group Inc. now owns 93,069 shares of the company’s stock worth $9,581,000 after purchasing an additional 9,052 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Barclays upped their target price on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. UBS Group increased their target price on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. Berenberg Bank boosted their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $135.00 price objective on shares of Merck & Co., Inc. in a research note on Thursday, April 18th. Finally, StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $131.33.

Get Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Down 1.2 %

MRK stock traded down $1.60 on Monday, hitting $129.49. 5,983,800 shares of the company’s stock were exchanged, compared to its average volume of 7,980,648. The firm has a 50 day moving average price of $128.15 and a two-hundred day moving average price of $119.79. Merck & Co., Inc. has a 12-month low of $99.14 and a 12-month high of $133.10. The stock has a market cap of $327.97 billion, a P/E ratio of 143.88, a price-to-earnings-growth ratio of 1.66 and a beta of 0.39. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. During the same quarter last year, the company earned $1.40 earnings per share. The company’s quarterly revenue was up 8.9% on a year-over-year basis. As a group, equities research analysts expect that Merck & Co., Inc. will post 8.69 EPS for the current fiscal year.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.